Skytrofa Injection, Powder, Lyophilized, For Solution
Product Images NDC 73362-014

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Skytrofa (NDC 73362-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascendis Pharma Endocrinology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (3 mg Cartridge Blister Pack Carton)

FDA Label Image

Principal Display Panel (3.6 mg Cartridge Blister Pack Carton)

FDA Label Image

Principal Display Panel (4.3 mg Cartridge Blister Pack Carton)

FDA Label Image

Principal Display Panel (5.2 mg Cartridge Blister Pack Carton)

FDA Label Image

Principal Display Panel (6.3 mg Cartridge Blister Pack Carton)

This is a pharmaceutical product with the NDC code 7336200701. The box contains skyter cartridges for injection, with a priming recommendation that advises against using them for the first time. There is further information on the amount of onapagomaropcgd and succine acid contained in each cartridge, along with cautions to seek training and healthcare provider advice. Additionally, there is a claim on the packaging that the product includes long needle cartridges, but the rest of the text is not available for reading due to errors.*

FDA Label Image

Principal Display Panel (7.6 mg Cartridge Blister Pack Carton)

FDA Label Image

Principal Display Panel (9.1 mg Cartridge Blister Pack Carton)

Not available. The text contains random characters and incomplete words that do not provide any meaningful information.*

FDA Label Image

Principal Display Panel (11 mg Cartridge Blister Pack Carton)

Skytrofa is a medication that comes in cartridges to be injected. It contains lonapeGsomatropin-egd and is used to treat growth hormone deficiency. The cartridges should only be used under the supervision of a healthcare provider. Dosage information is also included.*

FDA Label Image

Principal Display Panel (13.3 mg Cartridge Blister Pack Carton)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.